Document Classification

Section Type: RESULTS

Text: A primary efficacy outcome event occurred in 78 of 2938 patients (2. 7 %) receiving rivaroxaban and 82 of 2993 patients (2. 7 %) receiving enoxaparin at day 10 (relative risk with rivaroxaban, 0. 97 ; 95 % confidence interval [CI], 0. 71 to 1. 31 ; P = 0. 003 for noninferiority) and in 131 of 2967 patients (4. 4 %) who received rivaroxaban and 175 of 3057 patients (5. 7 %) who received enoxaparin followed by placebo at day 35 (relative risk, 0. 77 ; 95 % CI, 0. 62 to 0. 96 ; P = 0. 02).